Chairman and CEO David Koos noted, "Checkpoint inhibitors are a new class of drugs, which include Ipilimumab (Yervoy® Bristol Myers Squibb, 2018 estimated sales of $1.5 Billion1), and Pembrolizumab (Keytruda® Merck, 2017 sales of $3.4 Billion2). Current checkpoint inhibitors act to augment immune responses but do not have direct anticancer effects." By creating approaches to inhibit NR2F6, Regen BioPharma aims to develop a new class of checkpoint inhibitors that concurrently block tumor growth while enhancing the immune system.
Look at what “Checkpoint Inhibitors “ are worth!
News 
Market Data 
Discover 
